Trump Media is entering the nuclear fusion sector through a $6 billion merger with TAE Technologies. TAE aims to build its first utility-scale fusion plant by 2026. The deal highlights intensifying ...

President Donald Trump’s failing social media tech bid has tirelessly tried to reinvent itself into a viable business. The company, which owns Trump’s online megaphone Truth Social and is being run by ...

Trump media, the company behind the president's personal social media platform Truth Social, is inexplicably merging with a Google-backed fusion energy company called TAE Technologies. The deal is ...

Trump Media merged with fusion power company TAE Technologies. Trump Media & Technology Group (TMTG) on Thursday announced a $6 billion merger agreement with nuclear fusion company TAE Technologies, ...

Trump Media just announced a $6 billion deal with an Alphabet-backed outfit that would create one of the first publicly traded fusion companies. Reading time 2 minutes The parent company of Truth ...

Trump Media & Technology Group, the social media and crypto company part owned by President Trump, said it would help develop a “utility-scale fusion power plant.” By Matthew Goldstein Jonathan Wolfe ...

What if the key to solving the world’s energy crisis was hidden in a process so ambitious, so technically demanding, that even experts once dismissed it as science fiction? For decades, nuclear fusion ...

View post: Fast food chicken chain nearly gone after 1,000 stores close Oracle shares dropped after earnings missed revenue expectations. The company denied reports of OpenAI data center delays.

Oracle denies delaying OpenAI data centers to 2028 due to shortages Investors worried about Oracle's debt-fueled AI infrastructure buildout Market sensitive to AI delays, scrutinizing spending payoffs ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple ...

Oracle stock tumbled after its second-quarter report. Heavy spending on AI infrastructure has been slow to boost revenue, and profitability is a question mark. Investors appear to be skeptical of the ...

Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare disease biotech after an extremely tumultuous year for the latter that began with an FDA rejection at the end of 2024.